Nowe perspektywy leczenia wtórnie postępującej postaci stwardnienia rozsianego

• Authors: Magdalena Noga , Halina Bartosik-Psujek

Title variants

EN

New outlook for the treatment of secondary progressive multiple sclerosis

• Languages of publication: EN PL

Abstracts

EN

Multiple sclerosis is a chronic autoimmune disease of the central nervous system which has an unknown origin and variable course. In about 85% of cases it starts as the relapsing-remitting form that, in different periods of time depending on the patient, turns into the secondary progressive form with constant progression of disability, sometimes with preserved relapse and magnetic resonance imaging activity at the beginning. The treatment options for the secondary progressive form of multiple sclerosis are still limited. Based on the results of Mitoxantrone in Multiple Sclerosis Study, mitoxantrone has been registered for the treatment of secondary progressive multiple sclerosis. In addition, the drugs that have received registration in Europe are interferon beta-1b and interferon beta-1a given subcutaneously. These drugs have a proven effect in slowing the progression of disability (interferon beta-1b, mitoxantrone) as well as reducing the annualised relapse rate (interferon beta-1b, interferon beta-1a, mitoxantrone) and the number of new outbreaks in magnetic resonance imaging (interferon beta-1a, interferon beta-1b). The study of North American Study Group on Interferon β-1b in Secondary Progressive MS showed no effect of the therapy with interferon beta-1b on the inhibition of disability progression and as a result, the drug has not obtained registration for the treatment of secondary progressive multiple sclerosis in the United States. The patients who benefit most from the therapy which modifies the course of the progressive form of multiple sclerosis are younger, with a shorter history of the disease, preserved relapse activity and rapidly increasing disability.

PL

Stwardnienie rozsiane jest przewlekłą autoimmunologiczną chorobą ośrodkowego układu nerwowego o nieznanej przyczynie i zmiennym przebiegu. W około 85% przypadków najpierw występuje postać rzutowo-remisyjna, która po pewnym czasie (różniącym się w zależności od pacjenta) przechodzi w postać wtórnie postępującą ze stałą progresją niesprawności, niekiedy z początkowo zachowaną aktywnością rzutową i rezonansową choroby. Możliwości leczenia wtórnie postępującej postaci stwardnienia rozsianego są ograniczone. Na podstawie wyników badania Mitoxantrone in Multiple Sclerosis Study do leczenia tej postaci choroby zarejestrowany został mitoksantron. Ponadto w Europie rejestrację uzyskały interferon beta-1b oraz interferon beta-1a podawany podskórnie. Udowodniono wpływ tych leków na hamowanie progresji niesprawności (interferon beta-1b, mitoksantron) oraz spadek rocznego wskaźnika rzutów (interferon beta-1b, interferon beta-1a, mitoksantron) i liczby nowych ognisk w obrazach rezonansu magnetycznego (interferon beta-1a, interferon beta-1b). Badanie North American Study Group on Interferon β-1b in Secondary Progressive MS nie wykazało wpływu terapii interferonem beta-1b na hamowanie postępu niesprawności, więc nie uzyskał on rejestracji do leczenia tej postaci stwardnienia rozsianego w Stanach Zjednoczonych. Największe korzyści z terapii modyfikującej przebieg postępującej postaci choroby odnoszą pacjenci młodsi, chorujący krócej, z zachowaną aktywnością rzutową i szybko narastającą niesprawnością.

Keywords

EN

immunosuppression; immunosupresja; interferon beta-1a; interferon beta-1b; mitoksantron; mitoxantrone; multiple sclerosis; stwardnienie rozsiane

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2015
• Volume: 15
• Issue: 3
• Pages: 130–134

Contributors

author

Magdalena Noga

• Klinika Neurologii z Pododdziałem Leczenia Udaru Mózgu, Kliniczny Szpital Wojewódzki nr 2 w Rzeszowie, Polska. Kierownik Kliniki: prof. dr hab. n. med. Halina Bartosik-Psujek

author

Halina Bartosik-Psujek

• Klinika Neurologii z Pododdziałem Leczenia Udaru Mózgu, Kliniczny Szpital Wojewódzki nr 2 w Rzeszowie, Polska. Kierownik Kliniki: prof. dr hab. n. med. Halina Bartosik-Psujek

References

• Avasarala JR, Cross AH, Clifford DB et al.: Rapid onset mitoxantroneinduced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003; 9: 59–62.
• Biogen: Medical Information 1-866-MED-INFO (1-866-633-4636): TYSABRI (natalizumab): TYSABRI and Treatment of Secondary Progressive Multiple Sclerosis, 2015.
• ClinicalTrials.gov: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS). Available from: https://clinicaltrials.gov/ct2/results?term=ASCEND%2BNATALIZUMAB&Search=Search.
• ClinicalTrials.gov: FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS). Available from: https://clinicaltrials.gov/ct2/show/NCT00731692? =informs&rank=2.
• European Medicines Agency – Science, Medicines, Health: Betaferon. Interferon beta-1b. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000081/human_med_000673.jsp&mid=WC0b01ac058001d124.
• European Medicines Agency – Science, Medicines, Health: Rebif. Interferon beta-1a. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000136/human_med_001018.jsp&mid=WC0b01ac058001d124.
• European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497.
• Fleischer V, Salmen A, Kollar S et al.: Cardiotoxicity of mitoxantrone treatment in a German cohort of 639 multiple sclerosis patients. J Clin Neurol 2014; 10: 289–295.
• Hartung HP, Gonsette R, Konig N et al.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–2025.
• Kappos L, Weinshenker B, Pozzilli C et al.; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board: Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779–1787.
• Lublin FD: Oral fingolimod versus placebo in patients with primary progressive multiple sclerosis (PPMS): results of the INFORMS phase III trial. Presented at the American Academy of Neurology’s 67th Annual Meeting, April 18–25, 2015; Washington, DC. 006.
• Lublin FD, Reingold SC, Cohen JA et al.: Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–286.
• Martinelli Boneschi F, Vacchi L, Rovaris M et al.: Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013; 5: CD002127.
• Montalban X, Hemmer B, Rammohan K et al.; on behalf of the ORATORIO Clinical Investigators: Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis – results of the placebo-controlled, double-blind, Phase III ORATORIO study. Presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 7–10, 2015, Barcelona, Spain. 116701.
• Panitch H, Miller A, Paty D et al.; North American Study Group on Interferon beta-1b in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788–1795.
• Perini P, Calabrese M, Rinaldi L et al.: The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 2007; 6: 183–190.
• Riley CS, Tulliman MJ: Stwardnienie rozsiane. In: Rowland LP, Pedley TA: Neurologia Merritta. Vol. 3, Elsevier Urban &Partner, Wrocław 2010.
• Rommer MD, Stuve O: Management of secondary progressive multiple sclerosis: prophylactic treatment – past, present, and future aspects. Curr Treat Options Neurol 2013; 15: 241–258.
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496–1504.
• Sedel F, Papeix C, Bellanger A et al.: High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015; 4: 159–169.
• Tourbah A, Lebrun Frenay C, Edan G et al.: Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase III randomized double blind placebo controlled study. Presented at the American Academy of Neurology’s 67th Annual Meeting, April 18–25, 2015; Washington, DC. PL2.002.
• U.S. Food and Drug Administration: Mitoxantrone Hydrochloride (marketed as Novantrone and generics) – Healthcare Professional Sheet text version. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforpatientsand-Providers/ucm126445.htm.
• Zephir H, de Seze J, Duhamel A et al.: Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004; 218: 73–77.

• Document Type: review